Ensuring On-Time Release Of CAR-T Cell Treatment In Spain
Source: Marken, a UPS company
Due to the COVID-19 pandemic, and the start of Brexit, when the U.K. left the European Union (EU), many transport options were highly impacted. These circumstances caused the shipment to be offloaded multiple times by the airline. Based on the criticality of this shipment, an alternative transport solution was required.
Marken's goal was to ensure on-time release and delivery of an autologous CAR-T Cell Treatment therapy to an investigator site in Spain. This case study presents the outcome.
access the Case Study!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.
Subscribe to Clinical Leader
X
Subscribe to Clinical Leader
Marken, a UPS company
This website uses cookies to ensure you get the best experience on our website. Learn more